Keyword: Taiho Pharmaceutical
Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.
Biogen and Eisai defend Alzheimer's drug; Taiho and Servier's Lonsurf shows positive gastric cancer data; J&J pays $2.1 billion for Japan's Ci:z.
China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.
Not all Big Pharma's businesses in emerging markets are doing so well, Fosun is buying a smaller stake in Gland, Taiho and Arcus ink cancer option deal.
A month after Daiichi Sankyo announced plans for a major investment in cancer drug production, Japanese compatriot Otsuka said it is planning to do the same thing.